Plus Therapeutics IncNASDAQ:PSTVNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.6650
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.6000/ 10
- Ask / Lots1.6700/ 4
- Open / Previous Close1.6200 / 1.6650
- Day Range
- 52 Week Range
- Volume5,262
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PSTV |
|---|---|---|
| 09:32 ET | 115 | 1.62 |
| 10:32 ET | 100 | 1.5201 |
| 10:51 ET | 100 | 1.59 |
| 12:25 ET | 260 | 1.6099 |
| 12:27 ET | 200 | 1.61 |
| 01:03 ET | 212 | 1.6101 |
| 01:12 ET | 2100 | 1.63 |
| 02:04 ET | 265 | 1.65 |
| 02:18 ET | 218 | 1.6615 |
| 02:20 ET | 368 | 1.6436 |
| 02:38 ET | 500 | 1.665 |
Apr 22, 2024
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense, from 7:00AM ET on Monday Apr 22, 2024 by Dow Jones
7:00AM ET on Monday Apr 22, 2024 by Dow JonesPress Release: Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense, from 7:00AM ET on Monday Apr 22, 2024 by Dow Jones
7:00AM ET on Monday Apr 22, 2024 by Dow Jones
Apr 9, 2024
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team, from 7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
Mar 27, 2024
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference, from 8:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
8:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Plus Therapeutics Inc | 6.8M | -0.4x | --- |
Stemtech Corp | 6.0M | -0.9x | --- |
Kineta Inc | 6.8M | -0.4x | --- |
Aeterna Zentaris Inc | 9.4M | -0.6x | --- |
Petros Pharmaceuticals Inc | 4.4M | -0.1x | --- |
Athersys Inc | 277.7K | 0.0x | --- |
Company Information
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Contact Information
- Headquarters
- 4200 Marathon Blvd Ste 200AUSTIN, TX, United States 78756-3433
- Phone
- 858-458-0900
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Hawkins
- President, Chief Executive Officer, Director
- Marc Hedrick
- Chief Financial Officer
- Andrew Sims
- Vice President - Clinical Operations
- Pius Maliakal
- Chief Medical Officer
- Norman Lafrance
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.8M |
|---|---|
Revenue (TTM) | $4.9M |
Shares Outstanding | 4.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-4.51 |
Book Value | $-0.30 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -271.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
